2 models fit Chiron Real Estate Inc. Common Stock and they disagree: 0 of 2 land within 15% of the average.
Two or more of our models back this value.
Near fair value(i)
Valued as a REIT (property company): Price to FFO, Dividend discount, and EV/EBITDA comparison.
ACCE opinionChiron Real Estate Inc. Common Stock (XRN)
Fair value (2 models)
$27.57
ACCE price target
$33.00
Rating
Fairly valued
Horizon
12 months
Fair value published on 21 Oct 2026, 12:04 CEST; previously $25.81 since 16 Oct 2026, 00:00 CEST.
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 12:04 CEST.
Price used: $30.00 at the close on 23 Oct 2026, 22:00 CEST.
Models: Dividend discount and Price to FFO.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
8.8% above
-8.1% to fair value
ACCE score
44
out of 100
Analysts
45% buy
11 covering
P/E
8.1x
forward 714.3x
1-year return
-6.2%
Dividend yield
7.91%
Chiron Real Estate Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Chiron Real Estate owns and leases healthcare facilities, a REIT portfolio of medical office buildings, outpatient clinics and related properties rented to operators on long-term leases. The structural case rests on that lease structure: rent comes from contracted tenants rather than from patient volumes, and aging demographics keep demand for outpatient space rising. Revenue grew 4.8% and operating margin sits at 23.2%, with ROE of 10.4%, so the business is profitable on a modest asset base. The trailing P/E of 8.4 looks cheap, but the forward P/E of 714.3 signals that earnings are expected to fall sharply or that the forward estimate is thin, so the first thing to pin down is which it is. With a market cap of $454M, no index membership and a score of 49/100, this is a small, under-followed REIT where the cheap trailing multiple may be real or may be a trap, and it merits a deeper look at the earnings bridge and tenant concentration before anything else.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Free cash flow negative
Free cash flow is $-8,079,000 while debt/equity sits at 1.30, so the dividend-style cash generation the REIT profile implies isn't showing up in this period.
moderate
Earnings growth flat
Earnings are up 0.0% year over year against revenue growth of 4.8%, and the forward P/E of 714.3 suggests little expected earnings recovery.
moderate
Quarter-on-quarter softening
Revenue fell 0.9% quarter on quarter, and the ACCE score slipped from 45 to 44 over 90 days, a small but consistent drift lower.
AI research notes
AI-assisted·How I use AIWritten Oct 20, 2026 · figures from 2026-10-20 · prices to Oct 23, 2026
Why it could do well
Revenue grew 11.5% a year on average over five years, showing the business has expanded steadily over time.
Analysts' mean price target sits 30.0% above the current share price, and 45% of analysts rate the stock Buy or Strong Buy.
The company beat earnings expectations last quarter, with earnings per share of 0.88 against 0.83 expected.
Why it could disappoint
Free cash flow over the last twelve months was negative at -$8M, so the business did not generate spare cash from operations.
The share count rose 407.3% in the last fiscal year, heavily diluting existing shareholders' stakes in the company.
The stock trades 8.8% above the model fair value of $27.57, and the ACCE price target of $33.00 sits 9.1% above the current price.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where XRN's valuation models land
Price
$30.00
Model fair value
$27.57
Model range
$23.32 to $31.82
Fair value $27.57
Price $30.00
The price sits inside the model range.
Model
Fair value
Upside
Dividend discount
EV/EBITDA comparison
Price to FFO
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores